Provider Portal
Contact
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Leadership Team

About CIRCULOGENE

CIRCULOGENE was founded and is operated by proven leaders and scientists from the diagnostics industry. Via their guidance, CIRCULOGENE has been able to develop a proprietary cfDNA/cfRNA recovery technology and has incorporated best-in-class laboratory methods which result in the most complete and accurate menu offering of actionable markers. This makes CIRCULOGENE best-in-class for molecular cancer diagnostics. And – Patients deserve the best.

Leadership Team

President, CEO

Mike Mullen
Lab Director

Anthony L. Schmidt, M.D., F.A.C.P.
Vice President of Translational Medicine

Dr. Eric Thompson
Vice President of Laboratory Operations

J. Kevin Day, Ph.D., HCLD(ABB)
Chief Medical Officer

Dr. Paul Walker

President, CEO

Mike Mullen

Mike Mullen has more than 25 years in executive and financial leadership positions and has been involved with over $200M in liquidity and capital transactions during his career. Prior to founding Circulogene in 2015, he was the President and CEO of Atherotech Diagnostics, leading the Company’s expansion to over $120 million in revenue and led its sale to a private equity firm. He has held various C-level and financial positions with several companies, including Ernst & Young where he worked in the healthcare practice for over 6 years. Mike holds medical technology and accounting degrees from Auburn and UAB. In 2014, he was the Southeast recipient of the Ernst and Young HealthCare Entrepreneur of the Year Award.

Lab Director

Anthony L. Schmidt, M.D., F.A.C.P.

Dr. Anthony Schmidt is board-certified in anatomical and clinical pathology, and in hematology and transfusion medicine. His expertise in advanced diagnostics is focused on achieving improved patient outcomes through precision testing and clinical support. Dr. Schmidt earned his bachelor’s degree in chemistry at Florida Atlantic University and his doctor of medicine degree from the University of Miami School of Medicine in Miami, Florida. After completing his pathology residency at Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire, Dr. Schmidt received fellowship training in transfusion medicine and hematopathology from the University of Iowa Hospitals and Clinics in Iowa City, Iowa.

Vice President of Translational Medicine

Dr. Eric Thompson

Dr. Eric Thompson had years of experience managing and providing consulting services regarding biomarker research across a number of different organizations, including serving as Assistant Director of the Predictive Safety Testing Consortium (PSTC) at The Critical Path Institute. He has been involved in designing and enabling clinical use of molecular profiles for cancer patients. Dr. Thompson has extensive experience in the fields of pharmacology, toxicology, and molecular biology, and spearheaded the development of a proprietary evidence-based medicine engine. He is also responsible for working on business development efforts related to biomarker strategy and custom biopharma assay development. Prior to joining CIRCULOGENE, Dr. Thompson was a Paradigm Diagnostics founder and held the position of Vice President of Biomarker Research. Dr. Thompson has a Ph.D. in Pharmacology and Toxicology from the University of Arizona and did his Research Fellowship at the Mayo Clinic in Scottsdale.

Vice President of Laboratory Operations

J. Kevin Day, Ph.D., HCLD(ABB)

Dr. J. Kevin Day, Ph.D. is a seasoned laboratory operations leader in the clinical diagnostics arena.  His approach for laboratory excellence is the use of Lean Six Sigma methodologies to engage team members in driving continuous improvement initiatives and quality and cost efficiencies into laboratory processes. Dr. Day is certified through the American Board of Bioanalysis (ABB) as a High Complexity Clinical Laboratory Director (HCLD). His greater than 20 years of laboratory operations experience was gained across a broad diversity of genetic and genomic-based diagnostic testing methods (including Next Generation Sequencing) in a testing environment regulated by CAP, CLIA, New York State, AABB, and ISO 17025 and ISO 9001. Dr. Day did his doctoral studies at the University of Missouri-Columbia in Biochemical Genetics and his bachelor’s and master’s degrees at Brigham Young University in Molecular Biology.

Chief Medical Officer

Dr. Paul Walker

Dr. Paul Walker is the former Director of Thoracic Oncology at East Carolina University and has been the past Program Director and Chief of Hematology/Oncology for the Brody School of Medicine as well as the Medical Director for the Clinical Trials Office. Dr. Walker has multiple medical journal publications including cancer biotherapy with breast and lung cancers. Dr. Walker has been the principal investigator on multiple clinical trials including immune therapy, immune modulating and boosting therapies. He earned his medical degree from Indiana University School of Medicine, completed his residence at Ball Memorial Hospital, and his medical oncology fellowship at the Medical College of Ohio.

Back To Top